Biotech Startups

Kobiolabs (고바이오랩) develops microbiome-based drugs using its Smartiome platform, which applies AI-driven microbiome multi-omics analysis and a microbial library for drug discovery. The company focuses on immune, metabolic, and brain/neurological diseases, and uses a biofoundry-based microbe drug delivery system (mDDS).

3 investors

Kodikaz develops Zip-Code, a non-viral cell-specific delivery platform for gene therapy applications, particularly focused on oncology and cancer treatments. The company serves oncologists and patients with cancer seeking advanced therapeutic solutions.

3 investors

Komham develops microbial technology to decompose organic waste and sells biomass recycling systems based on that research. The company operates in the waste treatment and environmental technology sector in Japan.

3 investors

Koralo develops proprietary co-fermented microalgae and mushroom root ingredients that are clinically tested to support gut health, for use in human functional food and beverages as well as animal feed for aquaculture and pets. The company sells these ingredients to food and feed brands to improve digestive health, performance, and longevity.

3 investors

Korio provides RTSM (Randomization and Trial Supply Management) software for clinical trials, with a focus on experienced project management and continuity throughout the study lifecycle. The company serves clinical operations teams and sponsors managing treatment assignment and supply logistics in regulated pharmaceutical trials.

3 investors

Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology. It aims to create genetic medicines for patients with rare and highly prevalent debilitating or life-threatening diseases.

3 investors

Korsana develops technology to deliver large-molecule biologic drugs across the blood-brain barrier using transferrin receptor shuttling, aimed at treating neurodegenerative diseases such as Alzheimer's. Its approach uses antibody engineering to enable therapies with meaningful central nervous system exposure delivered subcutaneously.

3 investors

Kubanda develops innovative healthcare solutions for pets, focusing on pet wellness.

3 investors

Esencia Foods (now KULT FARM) uses mycelium solid-state fermentation with legumes to make vegan meat, fish, and hybrid meat products such as mince, chunks, and slices with clean labels. It sells to food service and retail businesses and has filed patents on its fermentation platform.

3 investors

Kultevat develops biomanufacturing using its Kultevar dandelion (TKS) to produce Kultra natural rubber and other biomaterials as regenerative, plant-based alternatives to petrochemical polymers like synthetic rubber. It partners with brands and manufacturers seeking to replace extractive rubber sourcing in their supply chains with materials made through regenerative agriculture.

3 investors

Kumquat Biosciences is a biotech company developing small-molecule cancer therapeutics, combining drug discovery and clinical expertise to advance new oncology treatments. It focuses on translating research into therapies for cancer patients.

3 investors

Kvantify develops software that runs on both quantum computers and classical computing architectures (CPU/GPU) to solve chemistry and biology problems for molecular and drug discovery. Its algorithms distribute calculations across quantum and classical compute resources in high-performance computing environments to accelerate the discovery of disease-curing molecules.

3 investors

KYNDA is a B2B technology company that uses submerged fungal fermentation to upcycle food and agricultural sidestreams into protein-rich mycelium ingredients. It provides end-to-end support, from cultures to hardware, enabling decentralised on-site fermentation for the food industry.

3 investors

Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.

3 investors

LabFellows provides a software platform for lab operations management, automating supplier ordering, inventory tracking, and compliance record-keeping for biotech organizations.

3 investors

Ladder Bio (formerly ThirdLaw Molecular) develops Spiroligomer molecules, a class of synthetic, modular fused-ring compounds designed for highly selective binding to target proteins, along with computational design tools for targeted drug discovery. The platform is aimed at creating therapeutics and diagnostic tests as synthetic alternatives to peptides and antibodies.

3 investors

Laguna Biotech is a biopharmaceutical company focused on discovering and developing new therapeutic approaches through science-driven research and clinical innovation.

3 investors

Lantern Pharma is a pharmaceutical biotechnology company that applies machine learning and AI to oncology drug development, using data-driven hypothesis testing with in vitro and in vivo models. Its approach stratifies patient populations into responders and non-responders to de-risk clinical trials, develop companion diagnostics, and improve the likelihood of FDA approval at reduced cost.

3 investors

LAVA develops the Gammabody platform, which generates bispecific antibodies that activate gamma-delta T cells to treat cancer by directing immune cells to tumors and triggering anti-cancer immune responses.

3 investors

Lavo Life Sciences offers computational molecular simulations to pharmaceutical companies, helping them optimize drug formulations, reduce experimental costs, and accelerate the path to clinical trials and regulatory approval.

3 investors

Laza Medical develops an AI- and robotics-powered ultrasound imaging system for structural heart, electrophysiology, and diagnostic cardiac procedures, combining real-time 3D heart modeling, procedural guidance, and robotic probe control. The system is aimed at clinicians and hospital care teams to simplify image guidance, and is not yet approved for sale in any country.

3 investors

LEAH Labs develops CAR-T cell therapy for pets, starting with dogs with B cell lymphoma, using a virus-free gene editing platform to produce engineered cell therapy doses at low cost. It targets general practice veterinarians across the USA, with a longer-term goal of extending its therapies to humans.

3 investors

LENZ Therapeutics is a pharmaceutical company developing and commercializing VIZZ™, an FDA-approved aceclidine-based eye drop for treating presbyopia, a vision condition affecting over 128 million people in the US. The company is focused on providing a once-daily pharmaceutical solution to restore near vision across a broad patient population aged 45 and above.

3 investors

Leon develops nanoparticle-based drug delivery systems for therapeutic applications in healthcare. The company leverages nanotechnology to improve drug efficacy and patient outcomes.

3 investors